A. J. Westermann, K. U. Förstner, F. Amman.,L.Barquist, Y.Chao, L.N. Schulte,L.Müller, R. Reinhardt,P. F. Stadler & J. Vogel. Nature (2016) doi:10.1038/nature16547
In close cooperation with New England Biolabs, Inc. (NEB), VERTIS is now able to make the new Cappable-seq method available to its customers. The method was developed by Laurence Ettwiller and Ira Schildkraut from NEB (Ettwiller, L. et al. 2016. BMC Genomics. 17, 1 (2016), 199).
It represents the current most sensitive and robust method for the precise identification of bacterial transcription start sites (TSSs).
we welcome you on the website of vertis Biotechnologie AG. We are a research-oriented company in the field of functional genomics. The strength of our service is customer-oriented flexibility which is based on our innovative technology platform which we have developed in our 16-year history.
We offer innovative tools and strategies for the comprehensive qualitative and quantitative analysis of bacterial and eukaryotic transcriptomes, using state-of-the-art Next Generation Sequencing (NGS) of RNA molecules (RNA-seq).
Special emphasis of VERTIS lies in the analysis of bacterial transcriptomes. We are able to provide specialised applications like dRNA-seq, tagRNA-seq, dual RNA-seq, Cappable-seq, etc., to our customers.
Our consequent use of a robotic system for NGS library preparation guarantees highly reproducible data, more consistent yields and higher quality data.
We offer a complete product line, ranging from project consulting, nucleic acid isolation, NGS library preparation, DNA sequencing to bioinformatic sequence analysis and data mining.
Our services cover the following areas: